Autopsy report · NCT06252623

Exenatide For Reducing the Reinforcing Effects of Cocaine

“The study was closed due to the inability to acquire the study drug.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Christopher D. Verrico

Sponsor type

University, hospital or other

Conditions

Cocaine Use Disorder

Interventions

Exenatide; Placebo

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
  “The study was terminated because we were not able to obtain the study drug.” (83% match in meaning)
• Panobinostat/Velcade in Multiple Myeloma
  “This study was terminated because the drug company stopped making the study drug” (80% match in meaning)
• One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease
  “The study was terminated early due to difficulty in enrollment and lack of clinical study drug access.” (78% match in meaning)
• Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia
  “The study was closed due to the end of funding.” (76% match in meaning)
• CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
  “Study drug no longer available” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.